News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
Clinical - Phase II
Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation In The United States And The European Union For The Treatment Of Malignant Pleural Mesothelioma 12/19/2014
AB Science (AB.PA): Report Of Positive Clinical Study Data In Metastatic Colorectal Cancer 12/19/2014
Innate Pharma (IPH.PA ): First Phase 2 Trial With IPH2201 Open In Head And Neck Cancer 12/19/2014
Amarantus BioSciences, Inc. Submits Orphan Drug Designation Application To U.S. FDA For Treatment Of Retinal Artery Occlusion With Product Candidate MANF 12/19/2014
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Results From The Phase 2 Borealis-1 Trial Of Apatorsen In The Treatment Of Metastatic Bladder Cancer 12/19/2014
Halozyme Therapeutics, Inc. (HALO) Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer 12/19/2014
Second Phase Of GlaxoSmithKline (GSK)'s Ebola Vaccine Delayed 12/19/2014
Xenetic Biosciences Completes Enrollment Of Second Cohort In Phase 2a Study With Erepoxen® For Anemia; Hemoglobin Levels Rise Into Therapeutic Range Over Time 12/19/2014
TetraLogic Pharmaceuticals (TLOG) Announces Initiation Of A Randomized Phase 2 Clinical Trial Of SHAPE In Subjects With Cutaneous T-Cell Lymphoma 12/18/2014
Fate Therapeutics (FATE) Announces Interim Data From Ongoing Phase 2 PUMA Study 12/18/2014
Biocryst Pharmaceuticals (BCRX) Initiates Opus-2: A Clinical Trial Of BCX4161 In Patients With Hereditary Angioedema 12/18/2014
StemCells Inc. (STEM) Transplants First Participant In Phase 2 Clinical Trial In Cervical Spinal Cord Injury 12/18/2014
Nuvo Research Inc. (NRI.TO) Reports That All Patients Have Completed Phase 2 Study Of WF10 For The Treatment Of Allergic Rhinitis 12/18/2014
D-Pharm Ltd. Achieves Primary End-Point In Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With tPA 12/18/2014
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Release: Study Further Validates Cell Therapy Approach To Reverse Type 1 Diabetes 12/18/2014
Ablynx (ABLYF) Opens Recruitment For First-In-Infant Phase 2a Study With Its Anti-Rsv Nanobody, ALX-0171 12/17/2014
Stemline Therapeutics, Inc. (STML) Initiates SL-401 Clinical Trial In Four Rare Myeloproliferative Neoplasms 12/17/2014
RXi Pharmaceuticals (RXII) Announces Sustained Effect Of RXI-109 At Three Months Post Scar Revision Surgery And The Completion Of Enrollment For Its Phase 2a Trial RXI-109-1301 12/17/2014
Pfizer (PFE) Initiates Phase 2 Study Of PF-06252616 In Duchenne Muscular Dystrophy 12/17/2014
Pivotal Therapeutics Inc. Release: VASCAZEN POMEGA Phase 2a Trial Protocol Cleared Clinical Evaluation By French FDA 12/17/2014
Velocity Pharmaceutical Development And Tigercat Pharma, Inc. Announce Phase 2 Results For VPD-737 In Patients With Chronic Pruritus 12/17/2014
First Patient Treated In Mapi Pharma's Phase 2a Clinical Trial Of GA Depot For Relapsing Remitting Multiple Sclerosis (RRMS) 12/17/2014
Poxel Announces Positive Top Line Results For Its Antidiabetic Agent Imeglimin In A Phase 2b Dose-Ranging Trial 12/17/2014
Bone Therapeutics Confirms Safety In ALLOB® Phase 1/2a Trial For Delayed-Union Fractures 12/16/2014
Neovacs SA Announces Top Line Phase 2b Clinical Trial Results Of TNF-Kinoid In Rheumatoid Arthritis And Update On Clinical Programs 12/16/2014
Anavex Life Sciences Corp. (AVXL.OB) Begins Enrollment Of Alzheimer's Patients In Phase 2a Clinical Trial Of ANAVEX 2-73 And ANAVEX PLUS 12/16/2014
Galapagos NV (GLPG.BR) Regains Full Rights To GPR84 Inhibitor GLPG1205 12/16/2014
GENFIT Corp. (ALGFT): Gft505 Treatment Prevents Evolution To Cirrhosis 12/16/2014
SOV Therapeutics Announces Successful Phase 2b Study Of Oral Testosterone Undecanoate For Treatment Of Primary And Secondary Hypogonadism In Adult Males 12/16/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 1/2 Study Of ISIS-DMPK Rx In Patients With Myotonic Dystrophy Type 1 12/16/2014
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Completion Of Patient Enrollment In The Rainier™ Clinical Trial Evaluating Apatorsen In Combination With ABRAXANEв Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer 12/16/2014
Why Gilead Sciences, Inc. (GILD) And AbbVie (ABBV) Are Keeping An Eye On Achillion Pharmaceuticals, Inc. (ACHN) 12/15/2014
VBL Therapeutics (VBLX) Announces Last Patient Out In Phase 2 Clinical Studies Of VB-201 In Psoriasis And Ulcerative Colitis 12/15/2014
Zafgen (ZFGN) Announces Initiation Of Phase 2b Trial Of Beloranib In Severe Obesity 12/15/2014
Araim Pharmaeuticals Release: New Study Published In Molecular Medicine Reports That Novel Agent Decreases Neuropathic Pain In Patients With Type 2 Diabetes 12/15/2014
Ascendis Pharma A/S Announces Positive Six-Month Interim Results From A Phase 2 Pediatric Study Of Once-Weekly Transcon Growth Hormone For The Treatment Of Growth Hormone Deficiency 12/15/2014
Can-Fite BioPharma (CFBI) Release: Second Part Of The Glaucoma Phase 2 Study Has Been Approved In A European Country 12/15/2014
Taiwan's TWi Biotech To Start Clinical Trial Of Gout Treatment 12/15/2014
Vaxil Publishes The Results Of Its Phase 1/2 Study Using Immucin In Myeloma Patients In The "British Journal Of Hematology" 12/15/2014
Astellas Pharma Inc. (ALPMY) Release: Data Presented From Phase 2 Study Of Enzalutamide In Advanced Androgen-Receptor Positive, Triple-Negative Breast Cancer 12/15/2014
Merck & Co. (MRK),NewLink Genetics Ebola Trial Suspended After Patients Complain Of Joint Pain 12/12/2014
ChemoCentryx, Inc. (CCXI) Announces Positive Results In Phase 2 Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140 12/12/2014
ChemoCentryx, Inc. (CCXI)To Host Conference Call On Friday, December 12, 2014 To Discuss Top-Line Phase 2 Results In Patients With Diabetic Nephropathy With CCX140, An Orally Administered CCR2 Inhibitor 12/12/2014
TWi Pharmaceuticals, Inc. Receives Approval Of Protocol For Its Drug Ac-201 Controlled-Release Tablet, Phase 2 Clinical Trial In Both The United States And Taiwan 12/12/2014
Kamada Ltd. (KMDA) Announces Positive Interim Results From Phase 1/2 Clinical Study Of Its Human Alpha-1 Antitrypsin To Treat Graft-Versus-Host Disease Presented At American Society of Hematology Annual Meeting 12/11/2014
Karyopharm Therapeutics (KPTI) Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330) 12/11/2014
International Breast Cancer Study Group, Breast International Group And Merck & Co. (MRK) Announce Opening Of International PANACEA Study Of Patients With HER2+ Breast Cancer 12/11/2014
Cellceutix (CTIX): Prurisol™ For Psoriasis -- FDA Agrees That Phase 2 Study May Begin 12/11/2014
Neurovance Announces Top-Line Study Results Suggest Lower Abuse Potential For Centanafadine Compared To Stimulants Used For Adult ADHD 12/11/2014
ARCA biopharma Announces Activation Of First Canadian Genetic-AF Clinical Trial Site 12/11/2014
FDA Grants BioMarin Pharmaceutical Inc. (BMRN) Orphan Drug Designation For NAGLU Fusion Protein, BMN 250, For The Treatment Of MPS IIIB (Sanfilippo Syndrome Type B) 12/10/2014
International Breast Cancer Study Group, Breast International Group And Merck & Co. (MRK) Announce Opening Of International PANACEA Study Of Patients With HER2+ Breast Cancer 12/10/2014
Naurex Inc.'s GLYX-13 Demonstrates Robust, Sustained Antidepressant Effects And Excellent Tolerability In Phase 2b Study 12/10/2014
Merck Announces Positive Data Investigating The Use Of Pembrolizumab In Patients With Advanced Triple-Negative Breast Cancer At 2014 San Antonio Breast Cancer Symposium 12/10/2014
Celgene (CELG) Release: Combination Of ISTODAX® (Romidepsin) And Standard CHOP Demonstrates A Complete Response In 51% Of Patients With Peripheral T-Cell Lymphoma 12/10/2014
Marina Biotech, Inc. (MRNA) Reports That Licensee ProNAi Therapeutics, Inc. Presented Interim Phase 2 Data On Its BCL2-Targeting DNAi® Therapeutic At American Society of Hematology 2014 12/10/2014
Bristol-Myers Squibb Company (BMY), Merck & Co. (MRK) Drugs Effective In Hodgkin Lymphoma Trials 12/9/2014
Ironwood Pharmaceuticals (IRWD) Initiates Phase 2a Clinical Study Of IW-9179 In Diabetic Gastroparesis 12/9/2014
Celgene (CELG) Release: REVLIMID® (Lenalidomide) Single-Agent And Combination Studies In Mantle Cell Lymphoma (MCL) Presented At American Society of Hematology 12/9/2014
OncoSec Medical Inc. Announces New Phase II Trial In Head And Neck Cancer Using ImmunoPulse 12/9/2014
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) In Combination With Rituximab Data Shows Positive Benefit-Risk Profile In Hematologic Malignancy 12/9/2014
Amgen (AMGN) Presents Data From Pivotal Phase 2 Study Of BLINCYTO (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia 12/9/2014
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) Data Demonstrates Safety And Durability Of Response At Two-Year Follow-Up In Mantle Cell Lymphoma 12/9/2014
Janssen Research & Development Release: IMBRUVICA (ibrutinib) Long-term Follow-up Data In Patients Living With Relapsed/Refractory Mantle Cell Lymphoma Show Almost Half Alive At Two Years 12/9/2014
Kiadis Pharma Presents Positive Data From A Pre Specified Interim Analysis Of The Phase 2 Clinical Program With Its Lead Product ATIR 12/9/2014
Promedior Presents Positive Phase 2 Data For PRM-151 In Myelofibrosis At American Society of Hematology Annual Meeting 12/9/2014
TG Therapeutics, Inc. (MHA) Release: Data From Phase 2 Clinical Trial Of TG-1101 (Ublituximab) And Ibrutinib Shows Compelling Clinical Activity In Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) 12/9/2014
Celgene (CELG) Release: New Data In Myelodysplastic Syndromes Presented At The 56th American Society of Hematology Annual Meeting And Exposition 12/9/2014
Isis Pharmaceuticals, Inc. (ISIS) Reports Positive Phase 2 Data For ISIS-FXI Rx For The Prevention Of Venous Thrombosis In Patients Undergoing Total Knee Replacement Surgery 12/8/2014
Orphan Drug Status Granted To Telormedix' Lead Product Vesimune For Bladder Cancer 12/8/2014
Generon (Shanghai) Corporation Ltd. Presents The Global Phase 2 Study Results For F-627 (Benegrastim) At American Society of Hematology 56th Annual Meeting At San Francisco 12/8/2014
Seattle Genetics, Inc. (SGEN) And Takeda (TKPYY) Announce Four-Year Survival Data From ADCETRIS® (Brentuximab Vedotin) Pivotal Trial In Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma At American Society of Hematology Annual Meeting 12/8/2014
Global Blood Therapeutics' GBT440 Demonstrates Ability To Positively Impact Fundamental Sickle Cell Disease (SCD) Processes In Studies Presented At 2014 American Society of Hematology Conference 12/8/2014
Threshold Pharmaceuticals, Inc. (THLD) Release: Encouraging Initial Data From Ongoing Phase 1/2 Trial Of TH-302 Plus Bortezomib (Velcade®) Plus Dexamethasone ("TBorD") In Patients With Relapsed/Refractory Multiple Myeloma Presented At American Society of Hematology Annual Meeting 12/8/2014
Ariad Pharmaceuticals, Inc. (ARIA) Announces Long-Term Safety And Efficacy Data Of Ponatinib From Phase 2 Pace Clinical Trial 12/8/2014
BioLineRx Ltd. Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at American Society of Hematology Conference 12/8/2014
Celgene (CELG) Release: New Data From Luspatercept Phase 2 Clinical Trial In Beta-Thalassemia Presented at the 56th American Society of Hematology Annual Meeting and Exposition 12/8/2014
Merck & Co. (MRK) Announces Positive Data Investigating The Use Of Pembrolizumab In Patients With Classical Hodgkin Lymphoma At American Society of Hematology Annual Meeting 12/8/2014
Amgen (AMGN) Announces New Data From Phase 2 BLINCYTO (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease 12/8/2014
Novartis AG (NVS) Highlights New CTL019 Clinical Data Showing Complete Remissions In Children And Young Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia 12/8/2014
Children's Hospital of Philadelphia Release: Benefits Persist In T Cell Therapy For Children With Relapsed Leukemia 12/8/2014
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) Data Suggests Promise In Multiple Myeloma 12/8/2014
MorphoSys AG And Xencor Publish Final Results From Phase 1/2a Trial Of MOR208 (Xmab5574) In CLL/SLL At Xencor Annual Meeting 12/8/2014
American Society of Hematology Release: New Strategies Boost Healthy Red Blood Cell Production To Target Anemia Across A Range Of Blood Disorders 12/8/2014
American Society of Hematology Release: Novel Combinations Of New And Existing Therapies Yield Promising Results for Leukemia Patients With Poor Prognoses 12/8/2014
AbbVie (ABBV) Presents Results from Phase 2 Study Of Investigational Compound Venetoclax (ABT-199/GDC-0199) In Acute Myelogenous Leukemia At The 56th American Society of Hematology Annual Meeting 12/8/2014
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Reports Significant Clinical Activity In Phase 2 Study Of Pracinostat In Front Line Acute Myeloid Leukemia 12/8/2014
Sangamo BioSciences, Inc. (SGMO) Presents New Data At American Society of Hematology Meeting Demonstrating Broad Application Of ZFN Mediated Genome-Editing Approach To Therapeutics For Hemophilia And Lysosomal Storage Disorders 12/8/2014
Phosphagenics Limited (POH.AX) Receives Ethics Approval To Commence Topical Phase 2 TPM®/Oxycodone Patch Trial 12/8/2014
Takeda (TKPYY) Presents Phase 2 Data On Maintenance With Single-Agent Investigational Ixazomib In Patients With Newly Diagnosed Multiple Myeloma 12/8/2014
OncoSec Medical Inc. Reports Positive Top-Line Six-Month Primary Endpoint Data From Phase II Melanoma Trial Of ImmunoPulse Monotherapy 12/5/2014
OncoSec Medical Inc. Says ImmunoPulse Tumor Drug Met Phase II Endpoints 12/5/2014
QLT Inc. (QLTI) Announces Results From Proof-of-Concept Trial With Oral Synthetic Cis-Retinoid (QLT091001) In Adult Subjects With Impaired Dark Adaptation And/Or Impaired Low Luminance Vision 12/5/2014
Cellular Biomedicine Group (CBMG) Releases Positive 48-Week Data From Phase I/2a Clinical Trial For Rejoin(TM) Treatment Of Knee Osteoarthritis (KOA) 12/5/2014
Celldex Therapeutics, Inc. (CLDX) Initiates A Phase 2 Study Of Glembatumumab Vedotin In Patients With Advanced Melanoma 12/5/2014
ProNAi Therapeutics, Inc. Reports Significant Activity And Ongoing Durable Responses In Relapsed Or Refractory Non-Hodgkin's Lymphoma With PNT2258 12/5/2014
CytRx Corporation (CYTR) Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials 12/4/2014
Acetylon Pharmaceuticals Initiates Phase 2 Study Of Ricolinostat (ACY-1215) In Combination With Pomalyst® 12/4/2014
Aerpio Completes Enrollment Of Phase 2 Study Of Tie2 Activator AKB-9778 For The Treatment Of Patients With Diabetic Macular Edema 12/4/2014
Isis Pharmaceuticals, Inc. (ISIS) Release: ISIS-APOCIII Rx Phase 2 Study In Patients With Familial Chylomicronemia Published In The New England Journal of Medicine 12/4/2014
Genmab A/S (GEN.CO) Announces Phase 2 Study Of Daratumumab In Non-Hodgkin's Lymphomas 12/4/2014
Apricus Biosciences (APRI) Announces First Patient Enrolled In Phase 2a Clinical Trial For Rayva In Patients With Raynaud's Phenomenon 12/4/2014
FDA Lifts Clinical Hold On Flexion Therapeutics (FLXN)'s FX006 For Osteoarthritis Pain 12/3/2014
Lpath, Inc. (LPTN) Completes Enrollment In Its Phase 2 Clinical Trial Of iSONEP For Wet Age-Related Macular Degeneration 12/3/2014
Minerva Neurosciences, Inc. (NERV) Announces Completion Of Development And Final Selection Of Once-Daily Dose Formulation Of MIN-101 For Its Schizophrenia Program 12/3/2014
Keryx Biopharmaceuticals (KERX) Release: Auryxia (Ferric Citrate) Phase 2 Data Published In The American Journal Of Kidney Disease 12/2/2014
Biothera Release: New Data Strengthens Correlation Between Biomarker And Cancer Immunotherapeutic Imprime PGG 12/2/2014
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Completes Enrollment In Phase 2 Study Of Pracinostat In Front Line Acute Myeloid Leukemia 12/2/2014
Xenetic Biosciences Partner Completes Dosing Of Second Cohort In Phase 2a Study Of Erepoxen® In Patients With Chronic Kidney Disease On Dialysis 12/2/2014
Momenta Pharmaceuticals, Inc. (MNTA)' Necuparanib Receives Fast Track Designation From The FDA For The Treatment Of Patients With Metastatic Pancreatic Cancer 12/1/2014
Dynavax Technologies Corporation (DVAX) Regains Full Rights To Investigational TLR 7/9 Inhibitor DV1179 Following Expiration Of Collaboration With GlaxoSmithKline (GSK) 12/1/2014
Jade Therapeutics Awarded $725k Phase 2 SBIR Grant From The National Science Foundation 12/1/2014
Galmed Pharmaceuticals Completes Analysis Of A Pharmacokinetic Study Of Aramchol In Healthy Volunteers 12/1/2014
Otonomy, Inc. (OTIC) Achieves Patient Enrollment Target In Phase 2b Clinical Trial Of OTO-104 In Meniere's Disease 12/1/2014
OncoMed Pharmaceuticals, Inc. (OMED) Begins Patient Dosing In Phase 2 Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) in Small Cell Lung Cancer 12/1/2014
Karyopharm Therapeutics (KPTI) Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission (EC) 12/1/2014
Takeda Pharmaceuticals’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation By U.S. FDA For Relapsed Or Refractory Systemic Light-Chain Amyloidosis 12/1/2014
TRACON Pharmaceuticals, Inc. Initiates Randomized Phase 2 Clinical Trial Of TRC105 In Patients With Renal Cell Carcinoma 12/1/2014
New Paper In Journal Of The American Chemical Society Documents Pioneering Discovery Of GalNAc-Conjugated siRNA By Alnylam Pharmaceuticals (ALNY) Scientists 12/1/2014
Data Published By Researchers From Leading Cancer Institutes Show Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Causes Tumor Cytotoxicity Through Previously Unidentified Mechanism 12/1/2014
Clementia Pharmaceuticals Receives Fast Track Designation For Palovarotene For Treatment Of Fibrodysplasia Ossificans Progressiva (FOP) 12/1/2014
Novartis AG (NVS) Fires Scientist Who Falsified Data In 6 Research Papers 12/1/2014
Amarantus BioSciences, Inc. Announces Positive Preclinical Data On The Effects Of MANF On Vision In A Model Of Retinitis Pigmentosa 11/25/2014
Afferent Pharmaceuticals Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency By 75% in Chronic Cough Is Published In The Lancet 11/25/2014
Milestone Pharmaceuticals Announces Positive Phase 1 Data For MSP-2017; Supports Advancement Into Phase 2 In PSVT Patients 11/24/2014
Synthetic Biologics, Inc. (SYN) Safe-To-Proceed Under IND To Initiate Clinical Trials Of SYN-004 For The Prevention C. Difficile Infection 11/24/2014
Transition Therapeutics Inc. (TTH.TO)' ELND005 Showed No Prolongation Of QT Interval 11/24/2014
The Journal of Clinical Endocrinology & Metabolism Publishes Radius Health's Phase 2 Study Of The Investigational Drug Abaloparatide In Postmenopausal Women With Osteoporosis 11/24/2014
Genmab, Inc. (GEN.CO) Announces Phase 2 Study Of Daratumumab In Smoldering Multiple Myeloma 11/24/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Publication Of REVEAL-1 Trial Results In The British Journal Of Haematology 11/24/2014
Xenetic Biosciences Partner Completes First Patient Cohort In Phase 2 Study With MyeloXen™ For Multiple Sclerosis 11/21/2014
University of Pennsylvania Doses First Patient In Phase IIa Clinical Trial Using CardioCell’s Stem Cell Therapy To Treat Chronic Heart Failure (HF) Due To Non-Ischemic Cardiomyopathy 11/21/2014
Proteo Inc. (PTEO.OB)/Proteo Biotech AG (PTEO.OB): Final Analysis Of The Phase II Clinical Study On Elafin In Coronary Artery Bypass Surgery Completed 11/21/2014
Clementia Pharmaceuticals Receives European Medicines Agency Orphan Medicinal Product Designation For Palovarotene For The Treatment Of Fibrodysplasia Ossificans Progressiva 11/21/2014
BioSpecifics Technologies Corporation (BSTC) Announces New Data On XIAFLEX For Peyronie's Disease Presented At SMSNA Scientific Meeting 11/21/2014
Intra-Cellular Therapies, Inc. Announces Additional Results From Phase I/2 Clinical Trial For ITI-007 In Healthy Geriatric Subjects And Patients With Dementia 11/21/2014
ChemoCentryx, Inc. (CCXI)'s CCX168, An Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation In Atypical Hemolytic Uremic Syndrome Treatment By The FDA 11/21/2014
Immunomedics, Inc. (IMMU) Announces Orphan Drug Designation For Veltuzumab For The Treatment Of Pemphigus 11/21/2014
NeoStem, Inc. Provides Further Information Regarding The Design Of The Phase 2 PreSERVE AMI Clinical Trial 11/21/2014
Clovis Oncology (CLVS) Release: Initial Data From Ongoing Phase 2 ARIEL2 Study Of Rucaparib In Ovarian Cancer Demonstrate Encouraging Clinical Activity And Safety In Both BRCA Mutant And Brcaness Patients 11/20/2014
Neurotrope Announces Last Patient Dosed In Phase 2a Clinical Trial Of Bryostatin-1 For Alzheimer's Disease 11/20/2014
Transition Therapeutics Inc. (TTH.TO) Announces Results From ELND005 Clinical Study In Adults With Down Syndrome 11/20/2014
St. Jude Children's Research Hospital Release: Gene Therapy Provides Safe, Long-Term Relief For Patients With Severe Hemophilia B 11/20/2014
DBV Technologies Initiates Phase I/2 Clinical Trial With Viaskin Milk For The Treatment Of Children With Cow's Milk Allergy 11/20/2014
PRANA Biotechnology (PRAN) Release: The Lancet Neurology Publishes Prana's Huntington Disease Trial 11/20/2014
Autifony Therapeutics Announces Initiation Of Phase 2a Study For First-In-Class Drug To Treat Tinnitus 11/20/2014
Neurotrope Announces Last Patient Dosed In Phase 2a Clinical Trial Of Bryostatin-1 For Alzheimer’s Disease 11/20/2014
Auxilium Pharmaceuticals (AUXL) Presents XIAFLEX For Peyronie's Disease Data At SMSNA Scientific Meeting 11/20/2014
Auxilium Pharmaceuticals (AUXL) Presents STENDRA Data At SMSNA Scientific Meeting 11/20/2014
NeoStem, Inc.'s Stem Cell Therapy Fails Mid-Stage Heart Attack Study 11/19/2014
Cynapsus Therapeutics (CYNAF) Announces Positive Top-Line Results From CTH-105 Phase 2 Study Of APL-130277 For The Treatment Of OFF Episodes In Patients With Parkinson's Disease 11/19/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Publication Of Vosaroxin Phase 1b/2 AML Trial Results In Haematologica 11/19/2014
Bio Blast Pharma Receives Orphan Drug Designation From U.S. FDA For Cabaletta For The Treatment Of Spinocerebellar Ataxia Type 3 11/19/2014
Synergy Pharmaceuticals Announces Positive Results Of SP-333 Phase 2 Trial In Patients With Opioid-Induced Constipation 11/19/2014
BIND Therapeutics (BIND) Presents Positive Phase 2 Results Highlighting Potential Of BIND-014 As Novel Anti-Cancer Treatment At Q3W Dosing Schedule For Patients With Non-Small Cell Lung Cancer At 26th EORTC-NCI-AACR Annual Symposium 11/19/2014
Tokai Pharmaceuticals (TKAI) Presents Updated Interim Galeterone ARMOR2 Data Showing Activity In Patients With Castration-Resistant Prostate Cancer (CRPC) Including Those Showing A Variant Form Of Prostate Cancer Resistant To Hormone Therapy 11/19/2014
PTC Therapeutics, Inc. (PTCT) Release: Spinal Muscular Atrophy Program Enters Phase 1b/2a Trial In Patients With SMA 11/19/2014
Amgen (AMGN) Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 11/19/2014
VGTI Florida To Collaborate With TapImmune Inc. (TPIV) To Advance Targeted Breast And Ovarian Cancer Vaccines Into Phase 2 Clinical Trials 11/19/2014
Omni Bio Pharmaceutical Announces Phase 1/2 Clinical Data Of AAT In Myocardial Infarction At American Heart Association Scientific Session 11/19/2014
Omeros Corporation (OMER) Release: OMS721 Inhibits Thrombus Formation In Sera from aHUS Patients 11/19/2014
UPDATE: Bionor Pharma ASA Announces That The Combination Of Vacc-4x + Revlimid(R) Is Well Tolerated And Increases CD4 Counts In People Living With HIV 11/19/2014
MabVax Therapeutics, Inc. And Memorial Sloan-Kettering Cancer Center Report On Potential Use Of Dual-Labeled Antibody To Detect And Guide Surgical Removal Of Pancreatic Cancer 11/19/2014
Bionor Pharma ASA Announces That The Combination Of Vacc-4x + Revlimid® Is Safe And Increases CD4 Counts In People Living With HIV 11/18/2014
Trevena, Inc. (TRVN) Announces Positive Top-Line Results From Phase 2a/b Study Of TRV130 In Acute Postoperative Pain 11/18/2014
NeoStem, Inc. Announces Initial Positive Data From Phase 2 Preserve AMI Clinical Trial 11/18/2014
Sarepta Therapeutics (SRPT) Announces First Patient Dosed In Confirmatory Study Of Eteplirsen In Ambulant Patients With Duchenne Muscular Dystrophy 11/18/2014
Juventas Therapeutics, Inc. Presents Phase 2 Data At American Heart Association Scientific Sessions That Shows JVS-100 Is Safe, Potentially Effective In Patients With Critical Limb Ischemia 11/18/2014
Innovative Med Concepts, LLC Release: Novel Fibromyalgia Treatment Shows Promise In Study 11/18/2014
Juno Therapeutics's JCAR015 Leukemia T Cell Therapy Granted Orphan Drug Designation By FDA 11/18/2014
ObsEva Announces The Initiation Of A Pivotal Phase 2 Study To Evaluate OBE001 For Improving Embryo Implantation And Clinical Pregnancy Rate In Women Undergoing IVF/ICSI 11/18/2014
Galena Biopharma  (GALE) Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial 11/18/2014
Levolta Pharmaceuticals Presents Phase 2 Study Results For Potential Osteoarthritis Therapy At American College of Rheumatology Annual Meeting 11/18/2014
Merck & Co. (MRK) Announces Positive Study Investigating The Use Of KEYTRUDA® (pembrolizumab) Compared To Chemotherapy In Patients With Ipilimumab-Refractory Advanced Melanoma 11/17/2014
Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 11/17/2014
NeuroSigma, Inc. Announces Top-Line Findings Of University of California, Los Angeles (UCLA) Phase 2 Clinical Trial Of eTNS For The Treatment Of Depression 11/17/2014
OrthoTrophix Completed Patient Treatments In Part A Of The Phase 2 Clinical Trial Of A New Cartilage Repair Therapeutic For Knee Osteoarthritis And Initiated Patient Enrollment For Part B 11/17/2014
AbbVie (ABBV) Presents Results From Study Of ABT-414 In Patients With Glioblastoma Multiforme At The 19th Annual Scientific Meeting And Education Day Of The Society For Neuro-Oncology 11/17/2014
Alder Biopharmaceuticals Inc. Release: Data From Phase 2b Clinical Trial Of Clazakizumab, An Anti-IL-6 Monoclonal Antibody For The Treatment Of Active Psoriatic Arthritis, To Be Presented At The American College of Rheumatology Annual Meeting 11/17/2014
MedImmune (AZN) Presents Promising New Data In Systemic Lupus At American College of Rheumatology Meeting 11/17/2014
MedImmune (AZN) Presents Positive Phase 2b Data For Mavrilimumab In Rheumatoid Arthritis At American College of Rheumatology Annual Meeting 11/17/2014
DelMar Pharmaceuticals' Promising New Data Support The Potential Of VAL-083 To Meet Significant Unmet Medical Needs In The Treatment Of Glioblastoma Multiforme 11/17/2014
Novavax, Inc. (NVAX) Initiates Phase 2 Clinical Trial Of Quadrivalent Seasonal Influenza VLP 11/17/2014
ChemoCentryx, Inc. (CCXI)'s Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements 11/17/2014
Ardelyx Inc. (ARDX)'s Tenapanor Reduces Phosphorus Absorption And Protects Against Vascular Calcification In Preclinical In Vivo Model Of Chronic Kidney Disease 11/17/2014
Naurex Inc. Release: Data Presented At Society For Neuroscience Demonstrates That Naurex's GLYX-13 Enhances Synaptic Plasticity Through NMDA Receptor Modulation 11/17/2014
Celldex Therapeutics, Inc. (CLDX) Release: Interim Update From Randomized Phase 2 ReACT Study Of Rindopepimut In Recurrent Bevacizumab-Naive Glioblastoma Demonstrates Statistically Significant Survival Benefit 11/17/2014
Alnylam Pharmaceuticals (ALNY) Reports Positive Initial Phase 2 Data With Revusiran 11/14/2014
Puma Biotechnology (PBYI)'s Cancer Drug Neratinib Fails Mid-Stage Study 11/14/2014
Chimerix, Inc. (CMRX)'s Brincidofovir Antiviral To Be Tested In West African Ebola Trial 11/14/2014
Chimerix, Inc. (CMRX)'s Brincidofovir Selected For Use In Ebola Clinical Trial In West Africa By International Consortium 11/14/2014
Puma Biotechnology (PBYI) Announces Positive Top Line Results From PB272 Phase 2 Trial In HER2 Positive Metastatic Breast Cancer (Nefertt Trial) 11/14/2014
ImmunoCellular Therapeutics, Ltd (IMUC) Presents Updated ICT-107 Phase 2 Data at the Society for Neuro-Oncology Annual Meeting 2014 11/14/2014
Viralytics Ltd (VLA.AX) Receives UK Approval To Commence Clinical Trial Of CAVATAK In Bladder Cancer 11/14/2014
AbbVie (ABBV)'s Hepatitis C Drug Cures 97 Percent In Phase 2 Transplant Patients Study 11/13/2014
Mesoblast Limited (MSB.AX)'s Phase 2 Trial Results In Chronic Low Back Pain Presented At North American Spine Society Annual Meeting 11/13/2014
Galmed Pharmaceuticals Announces First Administration Of Aramchol In Its Phase 2a Trial For The Treatment Of Cholesterol Gallstones 11/13/2014
ProLynx Awarded NSF Phase 2 Grant For Controlled Drug Release From And Degradation Of Hydrogel 11/13/2014
Clovis Oncology (CLVS) Announces First Patient Enrolled In TIGER-1 Study 11/13/2014
GenKyoTex S.A. Completes Enrollment Into Phase 2 Trial Of NOX1&4 Inhibitor GKT137831 In Diabetic Nephropathy 11/13/2014